RBP4 and obesity due to melanocortin 4 receptor deficiency: Fenretinide reduces circulating RBP4 levels, but the key importance of this effect in the therapeutic action of fenretinide is controversial, as it also prevents and/or reverses obesity, insulin resistance, and hepatic steatosis in Rbp4 knockout mice on HFD [183].